跳至主要内容
临床试验/NCT01159119
NCT01159119终止1 期

Single Center Randomized Single Blind Crossover Group Active Control Study to Evaluate Safety and Efficacy of EUR-1066 a Pancreatic Enzyme Product in Patients With Chronic Pancreatitis Exocrine Pancratic Insufficiency,Chronic Abdominal Pain

Forest Laboratories1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2010年8月2日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
终止
发起方
入组人数
15
试验地点
1
主要终点
Comparing frequency and severity of pain

研究概览

简要总结

The purpose of this study is to evaluate two different treatments in subjects with chronic pancreatitis, exocrine pancreatic insufficiency and chronic abdominal pain.

详细描述

To evaluate two different preparations of a pancreatic enzyme in subjects with chronic pancreatitis, exocrine pancreatic insufficiency, and chronic abdominal pain.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of Chronic Pancreatitis
  • Exocrine Pancreatic Insufficiency
  • Chronic abdominal pain

排除标准

  • Acute pancreatitis
  • Active alcohol consumption
  • Uncontrolled diabetes

研究组 & 干预措施

EUR-1066-A

Experimental

Treatment with Eur-1006-A.

干预措施: EUR-1066-A (Drug)

EUR-1066-B

Experimental

Treatment with Eur-1066-B

干预措施: EUR-1066-B (Drug)

Zenpep

Active Comparator

Control Group: Consist of treatment with Zenpep

干预措施: Zenpep (Drug)

结局指标

主要结局

Comparing frequency and severity of pain

时间窗: up to 84 days

Patient diary

次要结局

  • Changes in fat malabsorption(up to 124 days)

研究者

发起方
Forest Laboratories
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验